NA

Naturalendo Tech Co., Ltd

Biotech R&D of natural ingredients for health and wellness solutions.

168330 | KO

Overview

Corporate Details

ISIN(s):
KR7168330009
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로 255 번길 58, 에이동 301호, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Naturalendo Tech Co., Ltd. is a biotechnology company specializing in biosciences, herbs, and endocrinology. The company engages in the research, development, manufacturing, and sale of hormone biotechnology products, biological agents, and food additives. It focuses on developing health and beauty solutions derived from natural ingredients. The company's core activities revolve around the R&D and commercialization of new functional materials for the health and wellness sectors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-05-12 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 97.1 KB
2025-05-12 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-12 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-05-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 83.1 KB
2025-04-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 104.4 KB
2025-04-03 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 87.9 KB
2025-03-31 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등거래계획보고서
Korean 41.6 KB
2025-03-31 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 41.4 KB
2025-03-25 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 17.4 KB
2025-03-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 90.9 KB
2025-03-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-03-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.8 KB
2025-03-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB

Automate Your Workflow. Get a real-time feed of all Naturalendo Tech Co., Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Naturalendo Tech Co., Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Naturalendo Tech Co., Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LENZ Therapeutics, Inc. Logo
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America
LENZ
Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM

Talk to a Data Expert

Have a question? We'll get back to you promptly.